The Wellcome Sanger Institute
10
0
0
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 10 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
iSITE: Investigation of Somatic Alterations in Tumours of the Eye
Role: lead
SMS - Study of Somatic Mutations Using Genome Sequencing
Role: lead
SMS 2: Impact of Cancer Therapy on the Somatic Mutational Landscape of Normal Tissues
Role: lead
Retrospective WGS Study
Role: lead
Exploring the Landscape of Injury and Repair in the Human Oesophagus
Role: lead
Somatic Mutation in Chronic Liver Disease
Role: lead
Exploring the Landscape of Somatic Mutations in Human Tissue
Role: lead
Investigating How Childhood Tumours and Congenital Disease Develop
Role: lead
Investigating the Role of Genetics in Disease Predisposition
Role: lead
Sanger Human Cell Atlasing Project
Role: lead
All 10 trials loaded